Second Sight Medical Products (NASDAQ: EYES) and Amedica (NASDAQ:AMDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.
This table compares Second Sight Medical Products and Amedica’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Second Sight Medical Products||-565.12%||-184.87%||-137.77%|
This is a summary of current ratings and recommmendations for Second Sight Medical Products and Amedica, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Second Sight Medical Products||0||0||1||0||3.00|
Second Sight Medical Products currently has a consensus price target of $5.00, suggesting a potential upside of 170.27%. Amedica has a consensus price target of $60.00, suggesting a potential upside of 2,155.64%. Given Amedica’s higher probable upside, analysts plainly believe Amedica is more favorable than Second Sight Medical Products.
Volatility and Risk
Second Sight Medical Products has a beta of 3.45, indicating that its stock price is 245% more volatile than the S&P 500. Comparatively, Amedica has a beta of -1.82, indicating that its stock price is 282% less volatile than the S&P 500.
Valuation & Earnings
This table compares Second Sight Medical Products and Amedica’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Second Sight Medical Products||$3.98 million||26.41||-$33.17 million||($0.67)||-2.76|
|Amedica||$15.23 million||0.53||-$14.76 million||($1.93)||-1.38|
Amedica has higher revenue and earnings than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Amedica, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
12.7% of Second Sight Medical Products shares are held by institutional investors. Comparatively, 61.8% of Amedica shares are held by institutional investors. 34.7% of Second Sight Medical Products shares are held by company insiders. Comparatively, 0.1% of Amedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Amedica beats Second Sight Medical Products on 8 of the 14 factors compared between the two stocks.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
Amedica Company Profile
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.